title: Bench-to-bedside review: high-frequency oscillatory ventilation in adults with acute respiratory distress syndrome.
abstract: Mechanical ventilation is the cornerstone of therapy for patients with acute respiratory distress syndrome (ARDS). Paradoxically, mechanical ventilation can exacerbate lung damage--a phenomenon known as ventilator-induced lung injury. While new ventilation strategies have reduced the mortality rate in patients with ARDS, this mortality rate still remains high. High-frequency oscillatory ventilation (HFOV) is an unconventional form of ventilation that may improve oxygenation in patients with ARDS, while limiting further lung injury associated with high ventilatory pressures and volumes delivered during conventional ventilation. HFOV has been used for almost two decades in the neonatal population, but there is more limited experience with HFOV in the adult population. In adults, the majority of the published literature is in the form of small observational studies in which HFOV was used as 'rescue' therapy for patients with very severe ARDS who were failing conventional ventilation. Two prospective randomized controlled trials, however, while showing no mortality benefit, have suggested that HFOV, compared with conventional ventilation, is a safe and effective ventilation strategy for adults with ARDS. Several studies suggest that HFOV may improve outcomes if used early in the course of ARDS, or if used in certain populations. This review will summarize the evidence supporting the use of HFOV in adults with ARDS.
authors.affiliation: Department of Medicine, Mount Sinai Hospital and University of Toronto, 600 University Avenue #18-216, Toronto, Ontario, Canada.
authors.forename: James
authors.initials: J
authors.lastname: Downar
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Mehta
mesh_terms: D001794:Blood Pressure; D006339:Heart Rate; D006612:High-Frequency Ventilation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012128:Respiratory Distress Syndrome / Q000401:mortality / Q000628:therapy*